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In Brief
Crystal structures of the C-terminal domain of the principal inhibitory postsynaptic scaffolding protein gephyrin in complex with artemisinins together with biochemical and cellular analyses by Kasaragod et al . provide a comprehensive model for the regulation of inhibitory neurotransmission by artemisinins.
INTRODUCTION
Artemisinin is a sesquiterpene lactone containing an unusual endo-peroxide bridge that is produced by the plant Artemisia annua. Extracts of this plant have been used to treat malaria for centuries, and various artemisinin-based combination thera-pies (ACTs) now represent the standard anti-malarial drug regimen (Tu, 2016) . The World Health Organization strongly recommends ACTs for the treatment of malaria caused by Plasmodium falciparum. These treatments involve artesunate, a succinic acid derivative of artemisinin, in combination with amodiaquine or mefloquine, and also artemether in combination with lumefantrine (WHO, 2015) . In addition to the anti-malarial activity of these compounds, in mammals, artemisinin and its semi-synthetic derivatives (collectively known as artemisinins) have also been implicated in regulating the activities of multiple cellular targets, including an immunomodulation of various cancers (Crespo-Ortiz and Wei, 2012) . Recently, gephyrin, the central scaffolding protein of inhibitory postsynapses, was identified as a primary mammalian target of artemisinins (Li et al., 2017) . This interaction modulates the trans-differentiation (Li et al., 2017) of glucagon-producing pancreatic Ta cells into insulinsecreting Tb cells by regulating g-aminobutyric acid (GABA) signaling, thus suggesting an anti-diabetic potential of these compounds. Two subsequent studies, however, have questioned the trans-differentiation effect (Ackermann et al., 2018; van der Meulen et al., 2018) . Despite intensive research, the molecular action of these compounds remains to be defined.
GABA A Rs and GlyRs are the primary determinants of fast synaptic inhibition in the central nervous system (CNS). Both of these receptors belong to the Cys-loop pentameric ligand-gated ion channel family (pLGICs), which structurally consists of an extracellular domain (ECD) mostly composed of twisted b sheets, a four a-helical bundle transmembrane domain (TMD) and intracellular, highly unstructured loop regions (Du et al., 2015; Miller and Aricescu, 2014; Sigel and Steinmann, 2012) . GlyR b and a subset of GABA A Rs are primarily recruited and anchored to the postsynaptic membrane by the principal, multi-domain scaffolding protein gephyrin (Kirsch et al., 1991; Kneussel et al., 1999) . Gephyrin is composed of N-terminal (GephG) and C-terminal (GephE) structured domains connected via a highly flexible central linker (Prior et al., 1992) . GephG forms (legend continued on next page) a trimer and GephE forms a dimer in isolation (Kim et al., 2006; Schwarz et al., 2001) . Although the full-length protein has been recalcitrant toward crystallization, low-resolution small-angle X-ray scattering (SAXS) studies demonstrated that it is predominantly trimeric by utilizing the trimer interface of GephG for oligomerization (Sander et al., 2013) . The interactions of gephyrin with the GlyR b and GABA A R a1-3 subunits are mediated by a universal receptor-binding pocket located in GephE and the large intracellular loop connecting transmembrane a helices 3 and 4 (TM3-TM4) of the cognate receptor subunit Mukherjee et al., 2011; . Besides the receptor scaffolding function, gephyrin also interacts with various proteins to establish and maintain the architecture of inhibitory postsynapses (Kasaragod and Schindelin, 2018; Tyagarajan and Fritschy, 2014) , thus acting as the central organizer at the inhibitory postsynaptic density (iPSD).
As a moonlighting protein (Feng et al., 1998) , gephyrin catalyzes the terminal two steps of the evolutionarily conserved biosynthesis of the molybdenum cofactor (Moco). Specifically, GephG catalyzes the penultimate adenylation reaction of a tricyclic pyranopterin derivative designated molybdopterin in an ATP-dependent manner to form adenylated molybdopterin (AMP-MPT) as reaction intermediate (Kuper et al., 2004) . Subsequently, GephE deadenylates this intermediate coupled to the insertion of the metal present in the form of the molybdate anion into the dithiolene moiety of the pterin to form the mature Moco, which represents the essential active site component of the majority of Mo-containing enzymes (Kasaragod and Schindelin, 2016; Mendel, 2013) .
The loss of gephyrin is embryonically lethal, and dysfunctional gephyrin-mediated neurotransmission has been implicated in severe disorders, such as Alzheimer's disease, autism, schizophrenia, epilepsy, and also in hyperekplexia (Agarwal et al., 2008; Dejanovic et al., 2014 Dejanovic et al., , 2015 Fang et al., 2011; Hales et al., 2013) . In contrast, genetic deficiencies affecting the enzymatic activity of gephyrin manifest themselves in the rare yet severe molybdenum cofactor deficiency characterized by extensive neurological defects and early childhood death (Reiss and Hahnewald, 2011; .
Although artemisinins have been implicated in the regulation of a variety of mammalian cellular processes, in the absence of a single protein structure in complex with these drugs, an understanding of the molecular basis for the mechanism of action of these compounds remains elusive. The identification of gephyrin as the primary mammalian target of artemisinins (Li et al., 2017) prompted us to investigate the molecular mechanism of action of these compounds. Here, we present the first crystal structure of artemisinin or any of its derivatives in complex with a target protein, namely gephyrin. Artemisinins bind into the universal receptor-binding pocket residing in GephE, thus competing with inhibitory neurotransmitter receptors. Electrophysiological re-cordings and in cellulo data complement our structural findings, thus providing a unifying model for how artemisinins modulate inhibitory neurotransmission through gephyrin and also establish artemisinins as potential lead compounds for the treatment of neurological disorders.
RESULTS

Crystal Structures of GephE in Complex with Artesunate and Artemether
To understand the effect of artemisinins on gephyrin in vitro, we performed differential scanning calorimetry (DSC) experiments with artemisinin and two of its derivatives ( Figures 1A-1C) . Among the artemisinins being tested, artesunate stabilized GephE the most (by $2.1 C; Figure 1D ), at a level which is similar to the stabilization afforded by a high-affinity dimeric peptide derived from the GlyR b subunit . In contrast, artemether and artemisinin induced intermediate GephE-specific stabilizations by $1.4 C and $0.7 C, respectively (Figures S1A and S1B).
To better characterize the gephyrin-artemisinin interaction, we determined the crystal structures of GephE in the presence of artesunate and artemether at 1.5-Å resolution, which mapped the interaction at near-atomic resolution ( Table 1 ). The complex was obtained by soaking the compounds into crystals of the GephE-ADP complex, which allowed structure analysis by Fourier techniques. The GephE-ADP complex crystals belong to the orthorhombic space group I222 (Table 1) and contain one protomer of the GephE dimer in the asymmetric unit. GephE is composed of four subdomains, designated by Roman numerals, with subdomains III and IV engaging in interactions with the artemisinins (Figures 1E and 1F) . Initial Fourier analysis revealed significant difference density for both artesunate and artemether in the respective structure, located at the interface between subdomains III and IV, which allowed unambiguous modeling of these compounds ( Figures 1G-1M ).
Artemisinins predominantly engage in hydrophobic interactions with GephE, primarily mediated by Met326, Asp327, Phe330, and Ile331 from subdomain III and Pro654, Ile656, and Met711 from subdomain IV; in particular, the compounds are involved in a critical stacking interaction with Phe330 ( Figures  1I and 1J ). In the GephE-artesunate structure, which is characterized by a buried interface area of $360 Å 2 (corresponding to $60% of artesunate's total surface area), the carboxylate of artesunate also forms a tight electrostatic contact with Arg653. In comparison to the apo (Kasaragod and Schindelin, 2016) and also receptor-derived peptide structures (Maric et al., 2015) of GephE, the side chain of Arg653 moves toward the binding pocket by $2 Å , thus facilitating this electrostatic stabilization ( Figure 2A ). Corroborating the importance of this ion pair, a molecular dynamics (MD) simulation of the GephE-artesunate (I and J) An enlarged view of the artesunate (I) and artemether (J) binding pocket with critical residues and the ligand in stick representation along with 2F o -F c electron density at an RMS deviation of 1.5. Note that Met326 and Met711 adopt dual conformations. The red dashed line in the GephE-artesunate structure represents the electrostatic interaction of the artesunate carboxylate and the guanidinium group of Arg653. (K-M) 2D interaction map of (K) artesunate, (L) artemether, and (M) artemisinin with GephE generated with Molecular Operating Environment (MOE). The interaction map with artemisinin was derived from the GephE-artemisinin model, which was generated by taking the GephE-artemether structure as template. See also Figure S1 , Videos S1, S2, and S3, and Tables S1, S2, and S3. structure revealed that Arg653 remains in proximity of the carboxylate of the artesunate throughout the simulation with a median distance of 3.1-3.5 Å , despite occasional fluctuations and the solvent exposure of both groups (Tables S1 and S2; Video S1). Although artemether occupies the same binding pocket as artesunate ( Figures 1K and 1L ), engages in similar interaction, and buries a comparable amount of surface area ($326 Å 2 ), it differs substantially in the orientation of its endoperoxide bridge ( Figure 2B ). In addition, the interaction of artemether with GephE is also devoid of the electrostatic interaction with Arg653. MD simulations confirmed that binding of artemether is highly dynamic, and a stable pose is only adopted upon a shift of the Met711 side chain (Table S3) , which also explains the lower occupancy (0.8) of artemether ( Figure 1H ; Video S2) in comparison to artesunate. The latter compound, based on the electron density map and the similarity in the atomic B-factors of the drug and its interacting residues, is bound with full occupancy ( Figure 1G ). Because we could not obtain a structure of GephE in complex with the parental compound artemisinin, we investigated the dynamics of its binding to GephE by performing MD simulations with a GephE-artemisinin complex ( Figure 1M ) derived from the GephE-artemether structure as template. Similar to what was observed for artemether, artemisinin also undergoes remarkable conformational changes before eventually adopting a more buried pose (Tables S1 and S3 ; Video S3).
In its moonlighting function, gephyrin catalyzes the two terminal steps of Moco biosynthesis (Kuper et al., 2004; Kasaragod and Schindelin, 2016) . In the present study, the crystal structures Numbers in parentheses refer to the respective highest-resolution data shell in each dataset. a R sym = S hkl S i j I i -< I > j / S hkl S i I i , where I i is the i th measurement and < I > is the weighted mean of all measurements of I b R pim = S hkl 1/ (N-1) 1/2 S i j I i (hkl) À I (hkl) j / S hkl S i I(hkl), where N is the redundancy of the data and I (hkl) the average intensity c < I / sI > indicates the average of the intensity divided by its SD d R work = S hkl jjF o j -jF c jj / S hkl jF o j, where F o and F c are the observed and calculated structure factor amplitudes e R free same as R for 5% of the data randomly omitted from the refinement. The number of reflections includes the R free subset f Ramachandran statistics were calculated with MolProbity in PHENIX of GephE-artemisinins were determined in the presence of ADP, which is identical to one-half of the AMP-MPT substrate of GephE and occupies the active site located in subdomain III of GephE. The Moco biosynthesis active site and the artemisinin binding pocket in GephE are $25 Å apart as measured by the distance between two marker residues, Ser525 in the nucleotide binding pocket and Phe330 in the artemisinin or peptide binding pocket ( Figure S1C ). To understand whether the status of the artemisinin or peptide-binding pocket allosterically modulates nucleotide binding to GephE or vice versa, we compared the ternary GephE-drug-ADP and binary GephE-ADP (PDB: 5ERR) complexes (Figures S1D-S1G). This comparison revealed a root mean square (RMS) deviation of 0.71 Å and 0.82 Å for ADP in the artesunate-and artemether-bound structures, respectively, as well as RMS deviations of 0.15 Å (subdomain III of artesunate-bound GephE; Figure S1E ) and 0.14 Å (subdomain III of artemether-bound GephE; Figure S1G ) for the Ca atoms of the residues in the nucleotide-binding pocket, thus demonstrating the absence of significant structural rearrangements in the conformation of the bound ADP and in the residues in subdomain III, which mediate the binding of this diphosphate nucleotide. The lack of significant structural changes argues against drug-induced allosteric effects on the active site, which suggests an unaltered catalytic activity of the protein.
To further confirm the independence of the active site and the receptor or artemisinin binding pocket, we crystallized two additional ternary complexes, namely GephE in complex with ADP and two receptor-derived peptides, a decameric GlyR b-derived (Figures S1H-S1M) and a nonameric GABA A R a3-derived peptide that were crosslinked with a para-phenyl and polyethylene glycol (PEG)-derived crosslinker, respectively (Maric et al., 2015) . The high-resolution (1.55-1.95 Å ) ternary complexes were derived from crystals belonging to space group I222 (Table  1) , the same space group with nearly identical cell parameters as in the GephE-ADP-drug complexes, thus ensuring similar crystal packings and a meaningful comparison of all structures. Structural comparisons of the peptide-binding pocket in the ternary GephE-ADP-GlyR b ( Figure S1H ) and the GephE-GlyR b (PDB: 4U91)-bound complexes revealed that the nucleotide did not induce structural rearrangements in either the bound peptide or the residues that mediate peptide binding (RMS deviations of 0.52 Å for the peptide and of 0.40 Å for the Ca of the residues of the receptor-binding pocket; Figure S1I ). Similarly, comparison of the crystal structure of the ternary GephE-ADP-GlyR b-derived peptide complex with the binary GephE-ADP (PDB: 5ERR) complex did not indicate structural rearrangements in either the residues in the nucleotide-binding pocket in subdomain III ( Figure S1J ) or in the bound nucleotide (RMS deviations of 0.99 Å for the ADP and of 0.08 Å for the Ca atoms of the residues in the nucleotide-binding pocket). Similar RMS deviations were observed when comparing the ternary GephE-ADP-GABA A R a3-derived peptide complex (Figures S1K-S1M) with the binary GephE-ADP complex, which displayed RMS deviations of 0.71 Å and 0.08 Å for the ADP and the Ca of the residues of the nucleotide-binding pocket, respectively ( Figure S1M ). Likewise, the comparison with the GephE-GABA A R a3 (PDB: 4U90) structure displayed RMS deviations of 0.25 Å and 0.47 Å for the peptide and Ca of the residues of the receptor-binding pocket, respectively ( Figure S1L ). Thus, all structures indicate that the scaffolding and enzymatic functions of GephE are independent of each other.
Artemisinins and Inhibitory Neurotransmitter Receptors
Compete for an Overlapping Binding Site on Gephyrin Strikingly and even more importantly, the GephE-artesunate or GephE-artemether structures revealed that the artemisinins target the universal receptor-binding pocket ( Figures 2C and  2D ) responsible for the receptor-anchoring function of gephyrin (Kim et al., 2006; Maric et al., 2014a) . Most of the residues that are crucial for the gephyrin-artemisinin interaction are identical to those that mediate the gephyrin-receptor interactions. In particular, GephE Phe330 engages in crucial hydrophobic p-p stacking interactions with aromatic residues of the GABA A Rs a1-3 and GlyR b subunits, which were shown to critically contribute to the binding affinity . Detailed comparisons between the structures of the GephE-artesunate or GephE-artemether and GephE-receptor-derived peptide complexes revealed that the artemisinins inhibit the critical interaction of the N-terminal three residues ( 368 FNI 370 in GABA A R a3 and 398 FSI 400 in GlyR b) of the core binding region of the receptor ( Figures 2C, 2D , S2A, and S2B).
To check whether the compounds indeed modulate gephyrinreceptor interactions, displacement isothermal titration calorimetry (ITC) experiments with artesunate were performed. Receptor-derived, high-affinity dimerized variants of octameric GlyR-b-derived and decameric GABA A R-a3-derived peptides crosslinked with a PEG-crosslinker (Maric et al., 2015) were titrated to GephE in the presence or absence of the ligand. The calorimetric data in the presence of artesunate demonstrated an $5-fold decrease in affinity for GlyR (0.6 mM versus 3.3 mM; Figures 2E and 2F) and an $14-fold affinity reduction for GABA A R toward GephE (29 mM versus $380 mM; Figures 2G and 2H), thus demonstrating an artesunate-induced modulation of the gephyrin-receptor affinity.
To dissect the common and distinct molecular denominators of the receptor and artemisinins interaction with gephyrin, we also performed systematic site-directed mutagenesis of residues in the binding pocket ( Figures S2C and S2D ) and characterized the binding properties of the respective GephE mutants to artemisinins and/or receptor-derived peptides . The results clearly demonstrated that Phe330 ( Figure S2H ) is a common denominator of the receptor and artemisinin interactions, whereas Ile331 ( Figures S2I, S2J , S2M, and S2N) and Arg653 only play a role in the interaction with artemisinins ( Figures S2K and S2O ) and the Pro713Glu variant (Kim et al., 2006) selectively blocks receptor binding ( Figure S1G ).
Previous studies (Herweg and Schwarz, 2012; Maric et al., 2014b Maric et al., , 2015 demonstrated that the oligomeric state of gephyrin and the number as well as the arrangement of gephyrin-binding subunits in the pentameric GABA A Rs and GlyRs modulate binding strength and thus control postsynaptic receptor recruitment. Most of the in vitro binding studies involving gephyrin-inhibitory receptor interactions were so far carried out with either a recombinantly expressed 49-residue-long fragment derived from the TM3-TM4 loop of the GlyR b subunit or with short monomeric or dimeric receptor-derived peptide variants encompassing the core binding regions. Although the concept of dimerization mimics the avidity effect to some extent, the presence of more than one gephyrin-binding subunit in the receptors has been ignored so far. Thus, to recapitulate the avidity effects of gephyrin binding in the context of a pentameric arrangement of the receptor as well as to take into account possible membrane-binding effects, we applied a supported cell membrane sheet (SCMS) approach (Drees et al., 2005;  Figure 3A ). Membrane sheets presenting a homopentameric chimeric glycine receptor (GlyRa1b-gb) in which the TM3-4 loop of the gephyrin-binding b subunit has been engineered into the a subunit (Meier et al., 2000) allowed to quantitatively probe the interaction of full-length gephyrin (GephFL) with the pentameric receptors within their native membrane environment ( Figure 3B ) in the absence and presence of artesunate. Importantly, we found that artesunate at a concentration of 1 mM significantly modulated the binding of membrane-bound pentameric receptors ( Figures 3C and 3D ), resulting in an $7-fold affinity decrease (3.2 versus 20 nM), in good agreement with the calorimetric displacement measurements.
Effect of Artemisinins on Gephyrin in HEK293 Cells
Based on these observations, we moved to cell-based studies and first analyzed whether artemisinins affect the formation of gephyrin clusters in HEK293 cells, as GFP-labeled gephyrin is well known to form intramolecular aggregates in these cells (Kirsch et al., 1995) . Analyses of gephyrin and GlyR a1 expression of cells co-transfected with GlyRa1b and gephyrin revealed the formation of large intramolecular gephyrin aggregates (Figure 4A) , similar to cells transfected with gephyrin alone (Figure S3A) . Previous studies demonstrated that gephyrin forms large intracellular aggregates in HEK293 cells that are not directly correlated with the gene expression levels of gephyrin, rather a co-assembly of interacting proteins into these large cytoplasmic aggregates occurs (Fuhrmann et al., 2002; Maas et al., 2006) . Quantifications (Figures 4B-4E and S3B-S3F) revealed that, in the presence of artemether and artemisinin, the (C) Normalized intensity ratio binding isotherms of GephFL in the absence (magenta) or presence (blue) of 1 mM artesunate. Errors are shown as SEM of three individual experiments. Significance (**p = 0.0039) was tested using a two-way ANOVA using multiple comparisons (Sidak). (D) K d values and SEM obtained from fit in Figure 3C (*p = 0.029; unpaired two-tailed t tests). average intensities of gephyrin clusters were significantly increased, whereas intensities of clusters upon artesunate treatment were only marginally increased. In addition, artesunate and artemether led to significantly enhanced cluster perimeters (Figure 4B) and average intensities ( Figure 4D ) along with lower numbers of clusters per cell ( Figure 4C ). The areas of gephyrin clusters increased in a similar manner as the perimeter but did not reach significance ( Figure 4E ). The artemisinin-induced formation of gephyrin aggregates resembles earlier findings in pancreatic cell lines (Li et al., 2017) . Prompted by the formation of aggregates in cells, we also probed whether artemisinins induced higher order oligomers of gephyrin in vitro. However, atomic force microscopy (AFM) ( Figures S4A-S4F ) and multiangle light scattering (MALS) ( Figure S4G ) as well as native gel electrophoresis of GephFL and GephE (Figures S4H and S4I) failed to detect an artemisinin-induced higher order oligomerization of gephyrin.
To check whether the artemisinins directly affect the expression of the GlyRs, we probed the surface expression of the receptor. Using biotinylation of cell surface proteins expressed in transfected HEK293 cells, whole-cell proteins (WC) were separated from cell-surface proteins (SF) and quantified ( Figure 4F ). The quantification revealed that both the surface (Figures 4F and 4G) and the whole-cell expression of GlyR were not affected by artemisinins ( Figures S3G and S3H ). In summary, although we see changes in the morphology of aggregates in the presence of artemisinins in HEK293 cells, the total GlyR protein content neither changes significantly on the surface nor in the wholecell fraction.
Artemisinins Modulate Inhibitory Neurotransmission in a Time-Dependent Manner with an Obligatory Dependence on Gephyrin
It is known that super-binding peptides interacting with the universal receptor binding site of gephyrin act as acute modulators of fast synaptic inhibition (Maric et al., 2017) . It is tempting to speculate that artemisinins, which target the same binding site, could display a similar pharmacological effect. Therefore, we conducted electrophysiological measurements by performing whole-cell patch-clamp recordings in HEK293 cells at two different time points after 1 h and 48 h ( Figures 5A-5C , S5A, and S5B). HEK293 cells were either doubly transfected with heteromeric GlyR a1b or triply transfected with GlyR a1b together with gephyrin in the absence or presence of artemisinins. The resulting normalized currents (I 100 ) revealed a significant reduction in glycinergic currents in the presence of artemisinin and artemether after 48 h ( Figures 5A and 5B) for the triply transfected cells (Table S4 ) in comparison to the DMSOtreated cells. A slight decrease in glycinergic currents was also obvious upon artesunate treatment; however, it did not reach significance ( Figure 5C ). The presence of the GlyR b subunit in the GlyR complex was verified by measurements with glycine (legend continued on next page) (100 mM) and picrotoxin (100 mM). Homomeric GlyRs are blocked by picrotoxin to about 50%. In contrast, heteromeric GlyRs are almost unaffected by picrotoxin . The resistance to picrotoxin treatment was observed in all HEK293 cells triply transfected with GlyR a1b and gephyrin, thus arguing for an efficient incorporation of the GlyR b subunit into the receptor, which is followed most probably by the recruitment of gephyrin to the heteromeric GlyR complex ( Figures S5C and S5D ; see also Table S4 ). The observed significant inhibition of glycinergic currents after artemisinin treatment for 48 h was also seen at a lower level after a 1 h pre-incubation with artemisinins ( Fig Table S4 ); however, it did not reach significance. Hence, the regulation of gephyrin and receptor clustering and finally the influence on receptor functionality by artemisinins is a time-dependent process in transfected HEK293 cells. This relatively slow time-dependent regulation can also be explained in terms of continuous synthesis of novel proteins in the overexpression system, which might counteract the effect of artemisinins in transfected HEK293 cells.
Moreover, as seen with the gephyrin aggregation assay , the presence of artemisinins did not result in a decreased GlyR expression, arguing that the observed diminished glycinergic currents cannot be attributed to a lower cell surface expression of the receptors (Figures 4F and 4G) . These results confirm that the receptors and artemisinins bind in a mutually exclusive manner, which should result in reduced currents, as the stabilizing interaction between gephyrin and receptors are impaired in the presence of the drugs, thus altering the biophysical properties of the receptors.
In addition, we also investigated the impact of artemisinins on the GlyR-gephyrin interaction and glycinergic neurotransmission in a more physiological context ( Figures S5E-S5K ). We relied upon spinal cord neurons at day in vitro 13 (DIV13), which express GlyR a1 and the other a subunits as well as GlyR b, the essential subunit for the colocalization with gephyrin at postsynapses (colocalization with vesicular GABA transporter [VGAT]; Figure S5G ). Following verification of the expression of the receptors, whole cell current measurements were performed from spinal cord neurons DIV13-15, at the same time points, 1 h and 48 h, as in the HEK293 whole-cell patch-clamp recordings. Glycinergic currents were verified by application of the antagonist strychnine ( Figure S5E ), which, as expected, blocked the glycinergic currents. Neurons with a picrotoxin block of less than 70% corresponding to the expression of mainly heteromeric GlyRs were included in the analysis ( Figure S5F ). Strik-ingly, in contrast to DMSO treatment, glycinergic currents were significantly reduced in the presence of artemether and artemisinin already after 1 h, arguing for a rapid disruption of the receptor-gephyrin complex ( Figure 5D and upper panel of Figure 5E ). In the presence of artesunate, a significant reduction of glycinergic currents was only determined after 48-h treatment ( Figure 5D and lower panel of Figure 5E ). In contrast to the 1-h time point ( Figure S5H ), 48-h ( Figure S5I ) treatment with artemisinins leads to neuronal damage, as indicated by a reduced expression of synaptic and cytoskeletal markers. Similarly, in comparison with the 1-h treatment ( Figure S5J ), colocalization analysis after 48 h ( Figure S5K ) showed a remarkable reduction of GlyRs, in line with the observed neurofilament depletion.
Visualization of Artemisinin-Induced Gephyrin and Receptor Clustering in Hippocampal Neurons
Finally, we aimed to visualize the receptor-gephyrin-artemisinin interplay in a native environment and therefore conducted quantitative localization studies in hippocampal neurons. Initially, primary hippocampal neurons (DIV14) were stained for the GABA A R a2 subunit and the presynaptic marker protein SV2 after treatment with 50 mM artesunate for 24 h (Figure 6A ), which resulted in no prominent changes in parameters describing receptor clustering, such as cluster number per unit of dendrite length, area, and fluorescence intensity compared to the DMSO control ( Figures 6B and S6 ). However, an analysis of receptor clusters after a 1-h treatment with 50 mM artesunate revealed a significant decrease in all clustering parameters (Figures 6C, 6D, and S7) . At the same time, the presynaptic vesicle protein SV2 remained unchanged ( Figures 6E and S7 ).
Prior to dissecting the molecular mechanism of this timedependent regulation, we checked the expression of gephyrin, GABA A R a1, and also the presynaptic marker synaptophysin, as artemisinins have been shown to impart neurotoxic effects (Brewer et al., 1994a (Brewer et al., , 1994b Schmuck et al., 2002) , as also confirmed by our studies with spinal cord neurons. In addition, to check the viability of the hippocampal primary neurons, we also monitored the expression and integrity of the apoptotic marker poly ADP ribose polymerase (PARP) in neurons, which were treated with 50 mM artesunate at different time points. Western blot analysis ( Figure 6F ) and quantification displayed a significant reduction in the levels of gephyrin and GABA A R a1 after 24 h and later time points (Figures 6G and 6H ) and no change in the presynaptic marker synaptophysin ( Figure 6I increase in cleaved PARP fractions, and a significant reduction in actin levels was observed after 24 h or longer time points, thus indicating the onset of apoptosis ( Figure 6J ). These findings are in contrast to previous observations, which described no induction of apoptosis (van der Meulen et al., 2018) and an increase in gephyrin expression (Li et al., 2017) in pancreatic Tb and Ta cells, respectively, which were treated with artemisinins for up to 72 h. In addition, quantification of DAPI staining in hippocampal neurons also revealed a significant reduction in nuclear perimeter and area, indicative of a loss of nuclear integrity, corroborating the neurotoxic effects of artesunate when cells were treated for 48 h or longer ( Figures S8A-S8C ). Hence, we cannot rule out that the receptor cluster analysis after 24-h treatment with artesunate will be affected by cytotoxic effects. In contrast, we did not observe apoptosis at shorter time intervals (1-6 h of incubation), as reflected in the absence of cleaved PARP. Quantification of neuronal protein expression levels (gephyrin, PARP, and synaptophysin) in cells treated with 5 mM artesunate at different time points ( Figures S8D-S8H ) again confirm that the 1-to 6-h time window allows to study the effects of artemisinins on receptor clustering without interfering cytotoxic effects.
Hence, we focused on the shortest incubation time of only 1 h for the gephyrin-GABA A R a2-synaptophysin colocalization studies ( Figure 6K ), although we conducted these experiments also after longer incubations of up to 72 h ( Figure S8I ). Quantification of the colocalization experiments ( Figures 6L-6Q ) revealed a significant decrease in the gephyrin and GABA A R a2 areas and in the colocalization of gephyrin with a2 subunit containing GABA A Rs and, vice versa, of these receptors with gephyrin. At the same time, there was no reduction in the area of the presynaptic marker synaptophysin, indicating that the presynaptic side was not affected by artesunate; however, colocalization of gephyrin and a2 subunit containing GABA A Rs was reduced as expected. The colocalization studies hence confirm the competitive binding of artemisinins and GABA A Rs to gephyrin. Furthermore, a short-term treatment with artesunate is sufficient to disturb the receptor-gephyrin interaction without inducing cytotoxic effects, which are only apparent after treatment for more than 12 h.
DISCUSSION
Despite the diverse effects of artemisinins in the modulation of multiple signal transduction processes (Crespo-Ortiz and Wei, 2012; Tu, 2016) , the molecular mechanisms of regulation of any of these pathways have so far remained elusive. Recently, gephyrin was shown to be a mammalian target of artemisinins (especially artemether) and to modulate the trans-differentiation of glucagon-secreting Ta into insulin-secreting Tb pancreatic cells through the regulation of GABA A R-mediated signaling (Li et al., 2017) . However, subsequent studies argued against the observation of the anti-diabetic nature of these anti-malarial compounds, casting the mechanism of action of artemisinins into doubt without questioning the validity of the gephyrin-artemisinin interaction (Ackermann et al., 2018; van der Meulen et al., 2018) . In addition, the effects of artemisinins on the neuronal function of gephyrin were not investigated so far.
Finally, despite the widespread use of these clinically approved drugs, the structural framework of how artemisinins bind to a protein, either from Plasmodium or a mammalian target, could not yet be deciphered, thus preventing a full understanding of the mechanism of action of these compounds.
To elucidate the molecular mechanisms, we first performed DSC experiments of GephFL with artemisinin and two of its derivatives, which demonstrated a GephE-specific stabilization by these compounds (Figures 1D, S1A, and S1B) , at a level similar to the stabilization of GephE afforded by a GlyR-b-derived dimeric peptide, which tightly interacts with gephyrin . Structures of the GephE-artesunate or GephE-artemether complexes demonstrated that artemisinins not only partially occupy the prominent universal receptor-binding pocket but also inhibit critical contacts, which are the primary determinants of the interactions between gephyrin and inhibitory neurotransmitter receptors. Structural comparisons of the GephE-artesunate or GephE-artemether and GephE-receptor peptide-derived complex structures (Maric et al., 2015) revealed that the N-terminal three residues of the receptor are blocked by drug binding (Figures 2C , 2D, S2A, and S2B). Previous biochemical and structural studies have demonstrated that the aromatic residue at the N terminus of the core binding region of the receptor (Phe398 of GlyR b and Tyr340, Tyr339, and Phe368 of GABA A R a1-3, respectively; Maric et al., 2011) is one of the major determinants of the gephyrin-receptor interaction, and the stacking interaction of this aromatic residue with Phe330 of GephE is a prerequisite for the scaffolding function of gephyrin (Kim et al., 2006) . In the gephyrin-artemisinin complexes, this aromatic residue engages in hydrophobic interactions with the drug molecules.
Displacement ITCs and a membrane sheet assay demonstrated a noticeable reduction in the binding affinity of the gephyrin-receptor complexes in the presence of artemisinins. The first-time application of the membrane sheet assay (Figure 3) in a proof-of-concept experiment allowed us to monitor the interaction of gephyrin with a pentameric receptor, which revealed a comparable artesunate-induced reduction in gephyrin-receptor affinity as observed in displacement ITC studies. Although the use of a chimeric homopentameric GlyR represents a nonnative receptor, this assay can be extended in the future to other inhibitory receptors with native subunit compositions to gain additional insights into gephyrin-receptor interactions in a setting that more comprehensibly accounts for the avidity effects introduced by the presence of more than one gephyrin-binding subunit in GlyRs or GABA A Rs.
Although there are many common denominators that mediate both receptor and artemisinin binding to GephE, we were able to identify mutants that selectively abolish binding to either the receptors or artemisinins. Specifically, the I331W/Y variants abolish artemisinin binding while the GephE-receptor interaction remains intact, whereas the P713E variant only abrogates binding of GephE to the receptor without impairing the GephE-artesunate interaction (Figures S2E-S2O) . These variants will be valuable tools for future studies, which will delineate the selective mechanisms of specific cellular processes elicited by artemisinins.
Cell-based assays in HEK293 cells ( Figures 4A-4E ) as well as spinal cord (Figures S5G-S5K ) and hippocampal neurons ( Figure 6 ) confirmed our in vitro data by demonstrating reduced inhibitory glycinergic currents in the presence of the drugs and impaired inhibitory receptor-gephyrin colocalization with a rapid induction of these effects already after 1 h. The electrophysi-ology experiments with triply transfected (GlyRab-Geph) HEK293 cells displayed a significant reduction in glycinergic currents in the presence of artemisinins, thus demonstrating that disrupting the association between the intracellular domain of the receptor and a binding partner, in this case gephyrin, modulates the biophysical properties of the receptor. Such modulations have already been reported previously, for example, upon interaction of the TM3-4 loop with protein kinases A/C and also G-protein bg subunits (Lynch, 2004; Specht et al., 2011 Specht et al., , 2013 Yevenes et al., 2003 ). An even more rapid reduction in glycinergic currents already after 1 h was observed when spinal cord neurons were treated with artemisinins. This can be rationalized by the drug-induced disruption of the GlyR-gephyrin scaffold, which will allow a subset of the receptors to escape from the postsynaptic densities, which is expected to result in a decrease in the inhibitory currents. Nevertheless, an influence of artemisinins on presynaptic terminals and/or the extra-synaptic sites cannot be ruled out by the measurement of whole-cell currents. Therefore, future experiments, such as measurements of amplitudes and frequencies of synaptic currents, will be necessary to derive a comprehensive understanding of how these drugs modulate inhibitory neurotransmission.
In the in cellulo characterization of the effects of artemisinins in primary hippocampal neurons, gephyrin-positive areas were also significantly reduced in correlation with the reduction in receptor clusters after artesunate treatment as compared to the control, pointing to a destabilizing effect of artemisinins on gephyrin aggregates in the native neuronal environment. This is in line with previous observations describing an interdependency for GABA A Rs and the gephyrin scaffold (Craig et al., 1996; Essrich et al., 1998; G€ unther et al., 1995; Kneussel et al., 1999) . Detailed time-dependent studies of possible adverse consequences of longer artemisinin treatments revealed signs of cytotoxicity after 6-h treatment; thus, our studies also identify a time window in which the modulation of inhibitory neurotransmission by artemisinins can be analyzed, including a possible pharmacological intervention with these drugs (Figures 6F-6J ). The observed decrease in glycinergic synaptic transmission after artemisinin treatment for 48 h (Figures 5D, S5I , and S5K) is also in line with the neurotoxic effect of the drugs known from clinical studies, which are especially prominent at longer treatment periods (Brewer et al., 1994a (Brewer et al., , 1994b Schmuck et al., 2002) . This is not surprising because a loss of inhibitory neurotransmission is known to alter the physiologically critical balance of inhibition and excitation, resulting in neuronal excitotoxicity and finally apoptosis (Schwartz-Bloom and Sah, 2001) .
Comparing the effects of the three artemisinins under investigation, differences in the in vitro and in cellulo actions of artesunate are apparent. Although in the in vitro studies, artesunate exhibits the strongest effect, it is not as potent as artemether and artemisinin in electrophysiological recordings. This can be attributed to the instability of this compound, which, in human patients, is rapidly converted to the active metabolite dihydroartemisinin, most likely due to the action of plasma esterase (Gautam et al., 2009) . Even in the absence of suitable enzymes, artesunate loses its succinate moiety in aqueous solution, even at physiological pH. Hence, the instability of artesunate might contribute to apparent differences in in vitro versus in vivo observations already observed earlier (Zaman and Sharma, 1991) .
To better understand the specificity of artemisinins, a comparison of structures of different GephE homologs via ConSurf (Ashkenazy et al., 2016) and a corresponding sequence conservation analysis (Robert and Gouet, 2014) were carried out, which revealed that the residues mediating artemisinin binding are exclusive to mammalian orthologs, implying that these compounds only target mammalian gephyrin (Figure 7) . In addition, structures of ternary GephE-ADP-artemisinin and GephE-ADPpeptide complexes only exhibited minimal structural rearrangements in the active site of gephyrin required for Moco biosynthesis, thus arguing against an allosteric effect of artemisinin binding on Moco activity and no negative influence of artemisinins on the physiologically vital function of gephyrin during Moco biosynthesis.
In conclusion, our data describe an intricate interplay of GlyR/GABA A R signaling and the anti-malarial artemisinin drugs exerted through the specific binding of these drugs to gephyrin. We demonstrate that artemisinins modulate inhibitory neurotransmission with an obligatory dependence on gephyrin. One of the major challenges in the design of the drugs targeting the brain is to take into consideration the capacity of these molecules in crossing the blood-brain barrier. Remarkably, artemisinins have been shown to efficiently cross the blood-brain barrier (Davis et al., 2003) , and, as dysfunctions in gephyrinmediated neurotransmission have been implicated in multiple neurological disorders (Agarwal et al., 2008; Dejanovic et al., 2014 Dejanovic et al., , 2015 Fang et al., 2011; Hales et al., 2013) , our structures provide an excellent starting point for an artemisinin-based rational drug design campaign against neurodevelopmental disorders. Furthermore, the drug-induced, rapid time-dependent modulation of gephyrin and receptor clustering at postsynapses identifies a time window for drug application, which prevents cytotoxic effects. Thus, our structures not only provide a rational basis for the development of inhibitors modulating inhibitory neurotransmission but also establish artemisinins as a potent tool to impair neuronal activity, thus enhancing our basic understanding of the physiology and function of the human brain.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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DECLARATION OF INTERESTS STAR+METHODS
Hippocampi from female and male mice at embryonic day 16 (E16) were pooled and incubated with 0.05% (v/v) Trypsin/EDTA (Thermo Fischer, Waltham, MA #25300054) in HBSS (Thermo Fischer, Waltham, MA #14170112, no calcium, no magnesium, containing phenol red) for 5 min at 37 C. After washing once in HBSS supplemented with 10% (v/v) FCS (Invitrogen), cells were dissociated by trituration and seeded at a density of 80,000 cells per well onto 14 mm glass coverslips (Greiner Bio-One, Kremsm€ unster, Austria) coated with poly-L-lysine (5 mg/ml; Sigma, Steinheim, Germany #P2636; MW = 30,000-70,000) in Neurobasal PLUS neuronal culture medium (Thermo Fischer, Waltham, MA #A3653401, containing B27 PLUS supplement) with 2 mM L-glutamine (Thermo Fischer, Waltham, MA #25030081) and penicillin/streptomycin (Thermo Fischer, Waltham, MA #15140163; 100U/ml). Primary neurons were grown at 37 C, 5% CO 2 and 95% humidity.
To assess the effect of artesunate on protein expression levels, DIV21 (day in vitro 21) primary hippocampal neurons were used. Primary spinal cord neuronal cultures were prepared from pregnant female mice (CD-1 naive wild-type) at embryonic day 13 (E13). Mice were housed under a 12 h light/dark cycle and pathogen-free conditions with water and food ad libitum. Experiments were approved by the local veterinary authority and Committee on the Ethics of Animal Experiments (Regierung von Unterfranken) and were performed according to the guidelines of the European Union. E13 embryos (male and female) were sacrificed and spinal cords were dissected. Neurons were grown at 37 C with 5% CO 2 at 95% humidity in neurobasal medium with 2 mM L-glutamine and B27 supplement (Thermo Fisher Scientific) with an exchange of 50% medium after 6 d in culture. Neurons older than day in vitro 13 were used for electrophysiological recordings and immunoctyochemical stainings.
METHOD DETAILS
Recombinant protein expression and purification R. norvegicus Geph-FL (P2 splice variant, residues 1-750) in pET28b and GephE WT and mutants (F330A, I331W, I331Y, R653A and P713E) in the pTWIN1 vector were expressed in E. coli BL21DE3-RIL cells. For Geph-FL expression the culture was induced at an optical density (OD) 600 of 0.8 with 0.5 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) and grown for 16-18 h at 15 C. For expression of GephE, the culture was induced with 0.5 mM IPTG at an OD 600 of 1.0 and grown overnight at 30 C.
For GephFL initial purification was carried out by Ni 2+ -affinity chromatography, in contrast to GephE (WT and all mutants) where affinity chromatography was carried out by using chitin beads. The N-terminal intein tag of GephE was cleaved by a pH shift. Subsequently, anion exchange chromatography was carried out with a MonoQ 10/300 column (GE Healthcare). Finally, both proteins were purified to homogeneity by size exclusion chromatography (SEC; Superdex 200 26/600, GE Healthcare) in buffer containing 20 mM HEPES pH 8, 150 mM NaCl and 5 mM b-ME (SEC buffer).
Crystallization
For the crystallization of the GephE-ADP complexes, GephE (3 mg/ml) was incubated with 2 mM ADP and 5 mM MgCl 2 at 4 C for 30 min and crystallized by sitting drop vapor diffusion by mixing protein and mother liquor (0.02 M CaCl 2 , 0.1 M Na-acetate pH 4.5, 20%-36% 2-methyl, 2,5-pentanediol) in a 1:1 ratio at 20 C. Prior to soaking, all crystals were transferred stepwise into a solution containing 36% MPD (cryo-solution). Subsequently, crystals were soaked in solutions containing 3-15 mM artesunate or artemether supplemented with the cryo-solution for different time points ranging from 30 s to 14 h and flash frozen in liquid nitrogen. Data collection of GephE-ADP-artesunate complex crystals at 100 K was performed at ESRF on beamline ID30A-3 at a wavelength of 0.9677 Å and the data for GephE-ADP-artemether were collected on beamline ID30B at a wavelength of 0.9762 Å . For crystallization of the GephE-ADP-receptor derived peptide ternary complex, GephE (3 mg/ml) was incubated at a 1:4 molar GephE-peptide ratio and 2 mM ADP as well as 5 mM MgCl 2 at 4 C for 1 h. The complex was crystallized in mother liquor containing 0.1 M sodium acetate pH 4.5, 20%-36% 2-methyl, 2,5-pentanediol (MPD). Crystals were directly flash frozen in liquid nitrogen and data were collected at ESRF beamline ID30A-3 and BESSY beamline BL 14.1 at wavelengths of 0.9677 Å and 0.9180 Å , respectively.
Structure determination and refinement
Data were indexed, integrated, and scaled with XDS (Kabsch, 2010) and subsequently merged with AIMLESS (Evans and Murshudov, 2013) from the CCP4 suite . Structures were determined by molecular replacement with PhaserMR (McCoy et al., 2007) by using the GephE-ADP complex (PDB: 5ERR) (Kasaragod and Schindelin, 2016) as starting structure. Both complexes crystallized in space group I222 with one molecule in the asymmetric unit. Refinement was performed in PHENIX (Adams et al., 2010) with manual inspection in COOT (Emsley and Cowtan, 2004) . Anisotropic refinement of non-hydrogen protein atoms and the bound ligands (ADP and artesunate) was carried out for the GephE-ADP-artesunate structure whereas anisotropic parameters were refined only for the protein and ADP in the GephE-ADP-artemether structure. The inclusion of anisotropic B-factors resulted in a reduction by $2% in R work and R free . In addition, for the bound artemether, the occupancy was set to a 0.8. The GephE-GABA A R a3 dimeric and GephE-GlyR b dimeric structures were solved by molecular replacement (McCoy et al., 2007) and refinement was carried out in Refmac5 (Murshudov et al., 2011) as described previously. Coordinates and restraints for the ligands were generated with ProDRG (Sch€ uttelkopf and van Aalten, 2004) and figures containing structural representation were generated with PyMol or MOE.
Isothermal titration calorimetry
For the interaction studies and mapping of binding pocket residues of the gephyrin-artesunate interaction all GephE variants and the GlyR b19 peptide were dialyzed overnight into SEC buffer at 4 C. In contrast, for the displacement studies, dimerized variants of the GlyR-b/GABA A R peptides (Maric et al., 2015) were dialyzed overnight into ITC buffer. For measuring the GephE-artesunate interaction, 40 mL of 10 mM artesunate were titrated into 200 mL of 400 mM GephE at 37 C. In contrast, for the displacement studies, 0.5-2 mM of peptides were titrated into 50-100 mM GephE saturated with 5 mM artesunate. In all cases, 5% dimethylsulfoxide (DMSO) was maintained in both the cell and syringe to eliminate a contribution of DMSO to the heat signal. All displacement titrations were performed at 25 C. All data were corrected for the ligand to buffer titration. Owing to the low C-value for the titration of GephE with artesunate, the stoichiometry of 1:1 was kept constant to analyze the data and get a rough estimate of the dissociation constant for the interaction. Data were fitted with a one site binding model with the OriginLab software. Three measurements were performed with proteins derived from two independent purifications.
Differential scanning calorimetry (DSC)
Geph-FL was dialyzed into SEC buffer prior to DSC measurements with a NanoDSC (TA instruments). Calorimetric data were measured at a protein concentration of 20 mM in the absence and presence of ligands (5 mM). The measurements were carried out between 25-100 C at a scan rate of 1 min/ C. A blank buffer run with a corresponding DMSO concentration was carried out and subsequently subtracted from the data, which were analyzed with a two-state scaled model and the NanoAnalyze Software as described before . Two measurements were performed with proteins from two independent purifications.
Thermofluor assay
For determination of the melting temperatures, 1 ml of 200 mM of GephE variants was mixed with 1 ml Sypro-orange (1:100 diluted) and 23 ml of SEC buffer. Fluorescence emission was recorded between 25-95 C with a stepwise increase of 1 C. The analysis of the melting temperature was carried out with Microsoft Excel and a normalized curve is presented.
Size exclusion chromatography coupled to multi-angle light scattering (SEC-MALS) SEC-MALS experiments were performed by using a Superdex200 10/300 (GE Healthcare) column coupled to a Dawn Helios multiangle light scattering detector (Wyatt Technologies) which was pre-equilibrated with 20 mM HEPES pH 8.0, 150 mM NaCl, 5 mM b-ME and 5% DMSO. Measurements were performed with 100 mM GephE in the absence and presence of 5 mM artesunate. Differential refractive index (dRI) and light scattering (LS) were measured directly from which the molecular mass of the components was derived.
Native gel electrophoresis 1% native agarose gel (NAGE) and also 5% native polyacrylamide gel (PAGE) was prepared in 1x Tris-glycine buffer. Protein samples (GephFL and GephE) were incubated with DMSO and also artemisinin derivatives for 30 mins at room temperature prior to electrophoresis. For native agarose gel electrophoresis, the run was carried out for 5 h at 100 V and native PAGE was carried out for 30 min at 100 V. The gels were stained with Coomassie brilliant blue.
Atomic force microscopy (AFM)
Before AFM experiments, an additional SEC experiment of GephFL was performed with a Superose 6 increase 10/300 column (GE Healthcare) in SEC buffer. Protein samples were prepared in the apo-form or in complex with 1 mM artesunate and incubated at room temperature for 30 min. Samples (4 mM) were diluted into AFM buffer (25 mM HEPES pH 7.5, 25 mM Na-acetate and 10 mM Mgacetate) to final concentrations of 40 nM, 150 nM or 400 nM. The diluted samples were deposited onto freshly cleaved mica substrates, rinsed with deionized water, and dried in a gentle stream of nitrogen. A Molecular Force Probe MFP-3D-BIO atomic force microscope (Asylum Research) was used to perform image collection in oscillating mode with Olympus OMCL-AC240 silicon probes (spring constants of $2 N m À1 and resonance frequencies of $70 kHz). 2 3 2 mm 2 or 4 3 4 mm 2 images were captured at a scan speed of 2.5 mm/sec and a resolution of 1.95 nm/pixel. For data analysis, AFM images were flattened to third order using the Igor Pro-based MFP software (Asylum Research). ImageSXM (S. Barret, University of Liverpool) was used to measure the protein peak volumes. To derive the molecular masses of the protein molecules, the AFM volumes were compared with a standard curve obtained using calibration proteins (Roth et al., 2012) . Statistical analysis of protein molecular masses was achieved using the Origin software. Typically, molecular masses derived from AFM volume analysis are accurate to within 10% (Ratcliff and Erie, 2001) .
Supported cell membrane sheet binding assay (SCMS)
Semi-confluent HEK293-GripTite cells grown in DMEM 1965 with fetal calf serum (FCS) and pen/strep were washed in PBS and incubated with Opti-MEM (ThermoFisher Scientific 31985070), mixed with Lipofectamin 2000 (ThermoFisher Scientific 11668019) and 3 mg of cDNA encoding myc-GlyRa 1 bgb (GlyRa 1 bgb: Chimeric construct encoding GlyRa1 with its TM3-4-loop substituted with the corresponding residues of GlyR b, a gift from C. G. Specht (ENS, Paris) (Meier et al., 2000) for 16 h. Cells were washed in 10 mL PBS before seeding. Coverslips (round 15 mm, 0.17 mm thickness) were cleaned with oxygen plasma in a Harrick PDC-32G plasma cleaner for 20 min and transferred immediately into a well containing 0.2 mg/ml poly-L-ornithine (Sigma P3655) in PBS for 8-20 h. Before the addition of cells, coverslips were washed two times in MQ and DMEM 1965 with FCS and pen-strep (DMEM++) was added to the well.
Transfected cells were detached using 0.05% trypsin/EDTA solution (ThermoFisher Scientific 25300054) for 5 min at 37 C. Cells were counted using Trypan blue and 200,000 cells were seeded into each well containing a coated coverslip with DMEM 1965 with FCS and pen-strep. The transfected cells were grown for 24 h. The medium was removed, and cells were washed with assay buffer (10 mM HEPES, 120 mM KCl, 2 mM MgCl 2 , 0.1 mM CaCl 2 , 30 mM glucose, pH 7.35) and the well was filled with assay buffer after which an ultrasonic burst was applied (Branson Sonifier 250, 3 mm round tip, 20% output/1 s) in order to obtain supported cell membrane sheets (SCMS). Coverslips were washed once in assay buffer to remove cell debris and then incubated for 1 h with 1 mg/ml BSA in assay buffer at RT to block poly-L-ornithine coating. Prior to addition of the gephyrin/gephyrin-artesunate solution, coverslips were washed three times in assay buffer.
For sample preparation, artesunate (100 mM in 100% DMSO) was diluted into assay buffer and mixed with GephFL to reach a final concentration of 1 mM artesunate in 1% DMSO while varying the GephFL concentration (0-100 nM) for 1 h at RT. For the control samples, GephFL was mixed with 1% DMSO in assay buffer. The solution was transferred to a coverslip prepared with SCMS expressing the GlyRa1bgb. The reaction was carried out for 2 h at RT after which coverslips were washed three times in assay buffer and fixed immediately using 4% paraformaldehyde (PFA) in PBS for 20 min. Coverslips were then washed in 3x PBS and incubated for 16 h with primary antibodies (anti-Gephyrin mouse monoclonal 3B11 (SySy 147-111) 1:1,000 and anti-Myc monoclonal rat (Abcam 10910) 1:1,000) at 4 C.
Coverslips were washed three times with PBS and incubated with secondary antibodies (anti-rat Alexa 488, ThermoFisher A11029 1:500 and anti-mouse Alexa568, ThermoFisher A11077 1:500) for 2 h and washed additionally three times before additional fixation in 4% PFA for 20 min. Coverslips were mounted on a microscope glass slide using ProLong Gold Antifade (ThermoFisher P36930), left for 20 h at RT in the dark and afterward stored at 4 C. Imaging was done on a Zeiss LSM 510 laser-scanning confocal microscope, oil immersion objective (NA 1.4, 63x), equipped with 488 nm Argon-Krypton and 543 nm Helium lasers using 505-550/560-615 bandpass filters. Images were taken using 1024x1024 px, 8-bit, with eight average line scans. Images were quantified using ImageJ drawing a region of interest covering an integral part of the SCMS, avoiding oversaturated areas. The mean intensity of the ROI was measured and the intensity ratio between each channel was calculated and averaged. For each condition, five independent SCMS were imaged and quantified for three individual experiments (15 SCMS in total per condition). For each experiment, the averaged data were normalized using the background (no gephyrin added) as 0 and the B max of the fitted curve for the DMSO control as 100. Normalized data from all experiments were pooled and fitted (GraphPad Prism 7.0) using a three-parameter dose-response curve. The statistical significance of the individual points was evaluated by a two-way ANOVA with Sidak's multiple comparison post-test. The significance of the K d difference was evaluated using an unpaired t test (two-tailed) comparing the K d in the absence and presence of 1 mM artesunate.
Electrophysiology measurements HEK293 cells were transiently transfected using a modified calcium phosphate precipitation method. A mixture of plasmid DNA, CaCl 2 , 0.1xTE buffer and 2xHBS (50 mM HEPES, 12 mM glucose, 10 mM KCl, 280 mM NaCl, 1.5 mM Na 2 HPO 4 ) was applied to the cells. GFP, GlyR a1, GlyR b were used at a ratio of 1:1:2 (co-transfection with gephyrin at a ratio of 1:2:2). Media were exchanged after 6 h. The following day, 10 mM of DMSO, artesunate, artemether or artemisinin were added to different batches of cells. All experiments were done after 1 h or 48 h after incubation with DMSO, artesunate, artemether, and artemisinin. Current amplitudes (I 100 ) were measured by patch-clamp recordings in a whole-cell configuration. Current signals were amplified with an EPC-9 amplifier (HEKA, Lambrecht, Germany). Whole-cell recordings were performed by application of ligand (HEK293 cells: 100 mM glycine or 100 mM glycine with 100 mM picrotoxin; spinal cord neurons: 100 mM glycine, 100 mM glycine/100 mM picrotoxin, and 100 mM glycine/10 mM strychnine) using an Octaflow II system (ALA Scientific Instruments, New York, NY, USA) while bathing the suspended cell in a laminar flow of 100 mM glycine and giving a time resolution for equilibration of 10-30 ms. The external buffer for the HEK293 cells consisted of the following (in mM): 137 NaCl, 5.4 KCl, 1.8 CaCl 2 , 1 MgCl 2 , 5 HEPES, pH adjusted to 7.4 with NaOH. External buffer for spinal cord neurons (in mM): 142 NaCl, 8.1 KCl, 1 CaCl 2 , 6 MgCl 2 , 10 glucose, 10 HEPES, pH adjusted to 7.4 with NaOH. To block neuronal excitability and other ligand-gated ion channels, the external neuronal buffer was supplied with 1 mM TTX, 10 mM bicuculline, 10 mM CNQX, and 25 mM AP-5.
The internal buffer for HEK293 cells consisted of the following (in mM): 120 CsCl, 20 N(Et) 4 Cl, 1 CaCl 2 , 2 MgCl 2 , 11 EGTA, 10 HEPES, pH adjusted to 7.2 with CsOH and for spinal cord neurons (in mM): 153 KCl, 1 MgCl 2 , 5 EGTA, 10 HEPES, pH adjusted to 7.4 with CsOH. Recording pipettes were fabricated from borosilicate capillaries with an open resistance of 4-6 MU. Current responses were measured at a holding potential of À60 mV for HEK293 cells and À70 mV for spinal cord neurons. All experiments were performed at 22 C.
For each mean current value per compound (artesunate, artemether, and artemisinin) and transfection group (GFP, GlyRa1, GlyRb with/without gephyrin) the peak current amplitudes were obtained in total out of at least eight cells from three independent transfection experiments. Significance was tested via unpaired t tests (* p % 0.05; ** p % 0.01; *** p % 0.001).
Heterologous gephyrin expression in HEK293 cells and colocalization experiments in primary hippocampal and spinal cord neurons HEK293 cells were cultured on 14 mm glass coverslips (80,000 cells seeded per coverslip) pre-coated with poly-L-ornithine (1.5 mg/ml). 24 h later, cells were transfected with GFP gephyrin by calcium phosphate co-precipitation in the presence of 50 mM artesunate, artemether, and artemisinin, respectively, with DMSO as control. Cells were fixed and GFP gephyrin protein expression was analyzed 24 h after continuous drug treatment. 4',6-diamidino-2-phenylindole (DAPI; stock solution: 1 mg/ml in methanol; final working dilution: 1 mg/ml, 20 min incubation at room temperature) was used to counterstain the nuclei. Primary cultures of hippocampal neurons for confocal microscopy were prepared from mice at embryonic day 16 (E16). Hippocampi were incubated with 0.5 mg/ml papain and 10 mg/ml DNase I in PBS containing 10 mM glucose for 15 min at 37 C. After washing once in DMEM supplemented with 10% (v/v) FCS (Invitrogen), 25 mg/ml pyruvate, and 2 mM glutamine, cells were dissociated by trituration and seeded in DMEM containing supplements at a density of 80,000 cells per well onto 14 mm glass coverslips coated with poly-L-ornithine (1.5 mg/ml). After 3 h the medium was replaced with Neurobasal medium containing 2 mM glutamine, 25 mg/ml pyruvate, and 2% (v/v) B27 499 supplement (Invitrogen). All media contained 50 IU/ml penicillin and 50 mg/ml streptomycin (Invitrogen). Primary spinal cord neuronal cultures were prepared at embryonic day 13 (E13) of CD-1 wild-type mouse embryos. Experiments were authorized by the local veterinary authority and Committee on the Ethics of Animal Experiments (Regierung von Unterfranken). Mice were sacrificed and spinal cords were dissected. Spinal cord tissue was trypsinized using 5 mL of trypsin/EDTA (1 mg/ml) and 50 mL of DNase I (final concentration, 0.1 mg/ml) for 20 min at 37 C. Trypsinization was stopped with 500 mL of FCS (final concentration, 10%). Spinal cord neurons were triturated three times. Supernatants with cells were centrifuged at 800 rpm for 10 min. Cells were counted and plated on a 3 cm dish with poly-lysine-covered coverslips using a density of 150,000 cells/ dish. Neurons were grown at 37 C with 5% CO 2 at 95% humidity in neurobasal medium plus 5 mL of L-glutamine (200 mM) and B27 supplement (Thermo Fisher Scientific) with an exchange of 50% medium after 6 d in culture. Neurons older than day in vitro 13 were used for experiments.
Artemisinin stock solutions: Artesunate (100 mM), artemether (100 mM) and artemisinin (175 mM) were dissolved in DMSO and stored at room temperature. Working solutions of 10 mM in DMSO were prepared freshly at each day. Drugs were added to culture media at the indicated concentrations and treatment periods. For cell fixation, blocking, and staining, the following procedure was employed: Coverslips with primary hippocampal or HEK293 cells were washed with PBS and incubated in PBS containing 4% PFA (w/v) and 4% (w/v) sucrose for 12 min. Subsequently, cells were permeabilized for 4 min in 0.25% TX-100 (v/v) in PBS and afterward washed with PBS. Fixed cells were blocked with 1% (w/v) bovine serum albumin (blocking buffer; Roth). Antibody staining was performed by incubation for 1 h with primary antibodies and 45 min for secondary antibodies in blocking buffer. In between, cells were washed with PBS. For live staining experiments of GlyR a1, cells were incubated with the primary antibody mAb2b for 1 h at 4 C, and fixed/blocked/permeabilized thereafter to stain with other primary antibodies. For GABA A R a2 surface receptor expression staining, cells were fixed for 8 min in 4% PFA (w/v) and 4% (w/v) sucrose in PBS, washed with PBS and directly incubated with the primary antibody. For additional primary antibody applications, cells were permeabilized and processed as described above. DAPI was used in parallel with the secondary antibody to counterstain the nuclei. Fixed primary spinal cord neurons were analyzed with primary antibodies: neurofilament (chick polyclonal, Millipore; AB5539; dilution 1:250), GlyR pan-a (mouse monoclonal mAba, SySy; Cat. No. 147011; dilution 1:250). For live staining experiments, the GlyR a1 specific mouse monoclonal antibody mAb2b (SySy; Cat. No. 146111; dilution 1:500) was used. Secondary antibodies were: Alexa Fluor 488-conjugated goat anti-rabbit IgG (Dianova, Cat. No. 115-546-003; dilution 1:500), Cy3-conjugated anti-mouse (Dianova, ; dilution 1:500), Alexa Fluor 647-conjugated anti-chick (Dianova, ; dilution 1:500).
Fixed primary hippocampal neurons were analyzed with primary antibodies directed against: Gephyrin (mouse monoclonal antibody, clone mAb7a37, Synaptic Systems (SySy); Cat. No. #147011; dilution 1:300 for confocal microscopy), synaptophysin (guinea pig polyclonal antibody, SySy; Cat. No. #101 004; dilution 1:500 for confocal microscopy), SV2 (mouse monoclonal, clone SV2, DSHB; Cat. No. #SV2; dilution 1:100 for confocal microscopy), GABA A R a2 subunit (rabbit polyclonal, SySy; Cat. No. #224 103; dilution 1:250 for confocal microscopy). Secondary antibodies were: Alexa Fluor 488-conjugated goat anti-mouse IgG (Jackson IR, Cat. No. #115-545-146; dilution 1:500), Cy3-conjugated anti-rabbit (Jackson IR, 524 Cat. No. #711-167-003; dilution 1:500 for confocal microscopy), Cy5-conjugated anti-mouse (Jackson IR, Cat. No. #715-176-151; dilution 1:500 for confocal microscopy), Cy5-conjugated anti-rabbit pure Fab fragment (Jackson IR, Cat. No. #711-176-152; dilution 1:500). Fluorescence imaging was performed with a laser scanning confocal microscope (Fluoview FV 1000, Olympus) using a 63x objective. All pictures were single confocal sections, acquired using sequential scanning mode for simultaneous multi-channel fluorescence imaging and averaged four times to reduce noise. Co-localization indices were determined using the MetaMorph Imaging Software (Universal Imaging). For the quantification of co-localization in primary hippocampal cells the nucleus was excluded. Data were quantified based on 121 to 271 HEK293 cells and 32 to 36 neurons (1 h and 24 h time point) and 24 neurons (48 h and 72 h time point), respectively, for GABA A R a2 cluster analysis and QUANTIFICATION AND STATISTICAL ANALYSIS All programs used for quantification and statistical analysis are mentioned in the Method Details section in detail. Statistical analyses in this manuscript are described in the corresponding figure legends and also in detail in the Method Details section.
DATA AND SOFTWARE AVAILABILITY
Coordinates of GephE-artesunate and GephE-artemether structures have been deposited in the Protein Data Bank (PDB) with accession codes PDB: 6FGC and PDB: 6FGD, respectively, coordinates of the ternary complexes of GephE-ADP-GlyR b peptide and GephE-ADP-GABA A R a3 peptide have been deposited with the accession codes PDB: 6HSO and PDB: 6HSN.
